This article is more than 5 years old. Information may no longer be current.
Sienna Biopharmaceuticals announces financing for dermatologic therapies
Click Here to Manage Email Alerts
Sienna Biopharmaceuticals announced it has completed a $40 million, Series B financing to advance its diversified topical biotech pipeline.
The clinical stage medical dermatology and aesthetics company is developing lead assets including SNA-120 for pruritus and psoriasis, and SNA-125 for atopic dermatitis, psoriasis and pruritus, and through a photoparticle therapy platform, SNA-001 for treating acne vulgaris and permanent reduction of unwanted light-pigmented hair, according to a news release.
“We believe this financing will enable us to advance our development programs, which span pivotal clinical trials to preclinical programs,” Frederick C. Beddingfield III, MD, PhD, president and CEO of Sienna, stated in the release.
The financing was led by existing investors ARCH Venture Partners and Venvest Capital and additional investors including Partner Fund Management, Altitude Life Science Ventures and David Pyott, MBA. New investors, accounting for approximately half of the investments, included Fidelity Management and Research Company, certain investments funds advised by Clough Capital Partners L.P., and Omega Fund Management, according to the release.